Regional differences in the disease burden and attributable risk factors of female cancers DOI Creative Commons
Chunhui Li, Ke Peng

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 16, 2025

The aim was to assess the differences in burden and risk factors of female cancers among women aged 20-94 years across regions countries, order provide a reference for formulating tailored interventions. study analyzed incidence, deaths, disability-adjusted life (DALYs) using data from Global Burden Disease 2021 study. Age-period-cohort model evaluated effects age, period, cohort on burden, negative binomial regression explored association socio-demographic index (SDI) with burden. From 1990 2021, regional national DALYs varied markedly. Overall, SDI significantly positively associated incidence cancers, except cervical cancer (with relationship). High body-mass as leading factor uterine contributed higher such USA regions. Diet high red meat, unsafe sex, were breast cancer, respectively; however, other socioeconomic cultural should be considered, rural areas China lower A slightly increasing trend recent birth cohorts indicated effect generational experiences. disease has increased varies levels findings new insights into development targeted preventive measures specific region perspective social context.

Language: Английский

Temporal and geographical dynamics of early-onset Parkinson’s disease burden: insights from the Global Burden of Disease Study 2021 DOI Creative Commons
Yongle Li, Damien Tan, Cheng Luo

et al.

Frontiers in Neurology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 30, 2025

Introduction Early-onset Parkinson’s disease (EOPD) is a rare degenerative condition of the nervous system that primarily affects individuals working age. Its distinct clinical and genetic features make it critical area study in neurological research public health. Methods materials This analysis utilized data from Global Burden Disease Study 2021, covering 371 diseases injuries across 204 countries territories 1990 to 2021. The focused on aged 15–49 characterize EOPD. Data occurrence, frequency, mortality, disability-adjusted life years (DALYs) were collected. Sociodemographic measures used analyze patterns differences. Statistical methods, including joinpoint regression decomposition analysis, employed identify temporal factors influencing variations EOPD burden over time. Results global incidence saw significant increase between 2000 2009, with an average annual percentage change (AAPC) 4.3%, continuing at slower rate (AAPC 1.6%) 2010 By reached 2.1 cases per 100,000 population, up 1.0 1990. Males had higher 2.3%) compared females 0.8%). In 59.7% 81,047 male. Significant increases observed East Asia 5.1%), Andean Latin America 2.0%), North Africa/Middle 1.1%), decline High-income America. China highest 2021 (5.17 100,000), followed by Peru Bolivia. Saudi Arabia DALYs attributable indicated rise was mainly driven epidemiological changes population growth, regional impact. Conclusion highlights need for targeted interventions address gender-specific risk factors, disparities, effects growing burden.

Language: Английский

Citations

1
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux DOI Creative Commons
Ye Zhang, Jian‐Ge Qiu, Wei Wang

et al.

Experimental Hematology and Oncology, Journal Year: 2025, Volume and Issue: 14(1)

Published: Feb. 26, 2025

Abstract Background Ovarian cancer (OC) is the most pathogenic gynecological malignant tumor in world. Due to difficulty of early diagnosis, patients developed chemo-resistance and recurrence during/after chemotherapy. Methods CCK8 flow cytometry were utilized assess drug sensitivity apoptosis parental resistant cell lines. CYLD knockdown or overexpressed cells employed investigate its regulatory involvement DDP resistance. Clinical samples have been clinical relevance CYLD. The synergistic effects investigated through combination methods a nude mice model with ABCB1 inhibitor HER3 inhibitor. Results In this study, we found that levels significantly reduced DDP-resistant tissues compared normal cells. DDP-sensitive was sufficient converse become by reducing increasing Bcl-XL inhibiting Bax, efflux via upregulating expression. expression substantially higher cells, upstream facilitator suppressing STAT3 signaling. Furthermore, overexpression increased platinum-based chemotherapy both vitro vivo. key downstream target for regulating growth therapeutic resistance vivo, promoted translocation p65 nucleus which transcriptional activation. High rendered suppression, consequently, mediated blocking pathways promoting ovarian cancer. Conclusions Our findings identify novel HER3/CYLD/ABCB1 axis regulate resistance, may be used as potential target(s) overcome

Language: Английский

Citations

1
Review of electrophysiological models to study membrane potential changes in breast cancer cell transformation and tumor progression DOI Creative Commons
Chitaranjan Mahapatra,

A. Kishore,

Jineetkumar Gawad

et al.

Frontiers in Physiology, Journal Year: 2025, Volume and Issue: 16

Published: March 5, 2025

The transformation of normal breast cells into cancerous is a complex process influenced by both genetic and microenvironmental factors. Recent studies highlight the significant role membrane potential (Vm) alterations in this transformation. Cancer typically exhibit depolarized resting (RMP) compared to cells, which correlates with increased cellular activity more aggressive cancer behavior. These RMP Vm changes are associated altered ion channel activity, calcium dynamics, mitochondrial dysfunction, modified gap junction communication, disrupted signaling pathways. Such fluctuations influence key processes progression, including cell proliferation, migration, invasion. Notably, subtypes display frequent pronounced fluctuations. Understanding electrical properties provides new insights their behavior offers therapeutic targets, such as channels regulation. This review synthesizes current research on how various factors modulate proposes an electrophysiological model based experimental clinical data from literature. findings may pave way for novel pharmacological targets clinicians, researchers, pharmacologists treating cancer.

Language: Английский

Citations

0
FLOT1 Is a Novel Serum Biomarker of Ovarian Cancer Targeted by N6‐methyladenosine Modification Inhibition DOI Creative Commons
Bin Guan, Qi Lu, Junyu Chen

et al.

Cell Biology International, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

ABSTRACT Ovarian cancer (OC) is a deadly disease and lacks precise marker for diagnosis worldwide. Our previous work has shown the overexpression of flotillin‐1 (FLOT1) in OC tissue. To improve diagnostic sensitivity accuracy, we evaluated serum level FLOT1 patients found that concentration as well CA125 was significantly increased with compared healthy control ( p < 0.01) those benign tumors 0.05). The detection rate (above upper limit cut‐off value) 77.78% 72.22%, respectively, OC, which to 88.89% combination. elevation confirmed nude mice after implantation human cells. A high protein positively correlated tissues. Furthermore, m 6 modification mRNA cells normal ovarian epithelial cells, leading an increase expression. Application methylation inhibitor, 3‐deazaadenosine, decreased expression suppressed tumor formation xenograft mouse model. In conclusion, current study demonstrated novel biomarker can be targeted by inhibition. These data highlight potential application therapeutic target OC.

Language: Английский

Citations

0
Both complete response and long-term survival after combination therapy with toripalimab in a patient with meta-oligometastases cervical cancer: a case report DOI Creative Commons

Ge Jin,

Jun Wang

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 7, 2025

The therapeutic landscape for recurrent or metastatic cervical cancer remains limited, with few options available. According to National Comprehensive Cancer Network (NCCN) guidelines, pembrolizumab combined chemotherapy, without bevacizumab, is recommended affected patients. Despite these recurrence rates remain elevated, and survival outcomes following standard interventions are unsatisfactory. Furthermore, real-world management of presents inherent complexities, often requiring an integrative, multidimensional treatment approach enhance long-term survival. pressing need refine adopt multimodal strategies evident in addressing the persistent challenges associated disease progression. case involved a 40-year-old female diagnosed advanced who underwent radical hysterectomy. Postoperative pathology identified high-risk features, including lymph node involvement, necessitating adjuvant chemoradiotherapy. However, progression occurred during treatment, manifesting as metastases left supraclavicular axillary nodes. Subsequent local radiotherapy systemic therapy led favorable response. By November 2024, overall (OS) had surpassed 72 months, toripalimab administered 65 which no immunotherapy-related adverse events occurred. This offers clinical insight into efficacy safety integrating immunotherapy, cancer. contributes prolonged this patient. Further trials essential substantiate benefits regimen broader patient cohorts.

Language: Английский

Citations

0
Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database DOI Creative Commons
Huiping Zhang, Zhuo Zhou,

Juan Wang

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 8, 2025

Advanced cervical cancer remains associated with high mortality rates. While pembrolizumab has improved clinical outcomes in cancer, the therapeutic efficacy advanced stages is often compromised by immune-related adverse events (irAEs). This study aimed to systematically analyze pembrolizumab-associated (AEs) using FDA Adverse Event Reporting System (FAERS) database, providing new insights for optimizing practice. AE reports related were extracted from FAERS database (Q1 2016 Q4 2024). Disproportionality analyses performed multiple algorithms, including reporting odds ratio (ROR), proportional (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). AEs classified system organ class (SOC) preferred term (PT) based on Medical Dictionary Regulatory Activities (MedDRA), then ranked frequency signal strength. A total of 646 pembrolizumab-related identified. Age distribution peaked at 45-65 years cohort (32.75%), followed 18-44 (12.85%), 66-75 (11.76%), >75 (4.64%). Among 270 documented onset timelines, predominantly occurred 3-6 months after initiation (n=114, 41.36%). Clinical categorized as other (52.80%), hospitalization (27.00%), death (10.25%), unknown (6.06%), life-threatening (2.77%), disability (1.12%). Predominant involved hematologic, endocrine, dermatologic, neurologic, gastrointestinal, urinary, reproductive systems. real-world pharmacovigilance characterizes identifying high-signal such hematologic disorders, endocrine dysfunction, dermatologic toxicities. These findings provide critical evidence risk stratification safety monitoring practice, emphasizing need organ-specific vigilance during treatment window.

Language: Английский

Citations

0
Regional differences in the disease burden and attributable risk factors of female cancers DOI Creative Commons
Chunhui Li, Ke Peng

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 16, 2025

The aim was to assess the differences in burden and risk factors of female cancers among women aged 20-94 years across regions countries, order provide a reference for formulating tailored interventions. study analyzed incidence, deaths, disability-adjusted life (DALYs) using data from Global Burden Disease 2021 study. Age-period-cohort model evaluated effects age, period, cohort on burden, negative binomial regression explored association socio-demographic index (SDI) with burden. From 1990 2021, regional national DALYs varied markedly. Overall, SDI significantly positively associated incidence cancers, except cervical cancer (with relationship). High body-mass as leading factor uterine contributed higher such USA regions. Diet high red meat, unsafe sex, were breast cancer, respectively; however, other socioeconomic cultural should be considered, rural areas China lower A slightly increasing trend recent birth cohorts indicated effect generational experiences. disease has increased varies levels findings new insights into development targeted preventive measures specific region perspective social context.

Language: Английский

Citations

0